Lupin Expands US Inhalation Business With Two Sunovion Brands
Indian Firm Pays $75m For US Rights To Respiratory Brands Brovana And Xopenex HFA
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
